Table 1.
Basic characteristics.
| Variables, median | n = 91 patients |
|---|---|
| Age, years (IQR) | 64 (60, 67) |
| Abnormal DRE, n (%) | 35 (38.5%) |
| Prior to radical prostatectomy | |
| Prostate volume, ml (IQR) | 30.5 (23.7, 41.3) |
| Prostate weight, g (IQR) | 35.2 (27.6, 46.4) |
| tPSA, ng/ml (IQR) | 10.9 (7.5, 16.6) |
| fPSA, ng/ml (IQR) | 1.2 (0.7, 2.1) |
| %fPSA (IQR) | 12.1 (8.0, 16.1) |
| p2PSA, pg/ml (IQR) | 18.9 (11.9, 31.5) |
| %p2PSA (IQR) | 1.9 (1.2, 2.3) |
| PHI (IQR) | 54.6 (36.2, 79.2) |
| PSAD, ng/ml2 (IQR) | 0.4 (0.2, 0.6) |
| Clinical cancer stage, n (%) | |
| ≤T1c | 53 (58.2%) |
| T2a-2c | 38 (41.8%) |
| GS at TRUSP biopsy, n (%) | |
| ≤6 | 30 (33.0%) |
| 7 | 40 (44.0%) |
| ≥8 | 21 (23.1%) |
| Percentage of positive cores, % (IQR) | 20 (10, 40) |
| Maximum % of positive cores, (IQR) | 40 (16, 80) |
| Pathological results of radical prostatectomy | |
| Pathological stage, n (%) | |
| pT0 | 2 (2.2%) |
| pT2 | 58 (63.7%) |
| pT3 | 30 (35.2%) |
| pT4 | 1 (1.1%) |
| Pathological GS, n (%) | |
| ≤6 | 7 (7.9%) |
| 7 | 66 (74.2%) |
| ≥8 | 16 (18.0%) |
| Positive lymph node, n (%) | 10 (11.9%) |
| Positive surgical margin, n (%) | 43 (47.3%) |
| Upgrade of GS compared with the biopsy, n (%) | 26 (28.6%) |
| High-risk disease, n (%) | 36 (39.6%) |
IQR: interquartile range; DRE: digital rectal examination; PSA: prostate specific antigen; tPSA = total PSA; fPSA = free PSA; %fPSA = percentage of free to total PSA; p2PSA: [−2]pro PSA; %p2PSA = (p2PSA/fPSA × 1000) × 100; PHI: Prostate Health Index; PSAD: PSA density; GS: Gleason score; TRUSP: transrectal ultrasonography of the prostate.